Radius Health, Inc. (NASDAQ:RDUS) had its price objective reduced by Jefferies Group LLC from $38.00 to $31.00 in a research report report published on Friday morning. Jefferies Group LLC currently has a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on RDUS. Zacks Investment Research upgraded Radius Health from a sell rating to a hold rating in a research report on Tuesday, August 8th. BidaskClub downgraded Radius Health from a buy rating to a hold rating in a research report on Tuesday, July 11th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the stock a buy rating in a research report on Sunday, July 23rd. Goldman Sachs Group, Inc. (The) reiterated a neutral rating and set a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. Finally, Canaccord Genuity set a $85.00 target price on Radius Health and gave the stock a buy rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $51.00.

Shares of Radius Health (NASDAQ:RDUS) opened at $28.71 on Friday. Radius Health has a 52-week low of $27.16 and a 52-week high of $55.97. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period last year, the business posted ($1.07) EPS. sell-side analysts predict that Radius Health will post -5.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Jefferies Group LLC Cuts Radius Health, Inc. (RDUS) Price Target to $31.00” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/jefferies-group-llc-cuts-radius-health-inc-rdus-price-target-to-31-00/1685323.html.

In other news, major shareholder Growth N. V. Biotech bought 150,000 shares of Radius Health stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the acquisition, the insider now owns 5,113,799 shares of the company’s stock, valued at approximately $178,829,551.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jose Carmona bought 3,000 shares of Radius Health stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $32.83 per share, with a total value of $98,490.00. Following the completion of the acquisition, the chief financial officer now directly owns 3,000 shares of the company’s stock, valued at approximately $98,490. The disclosure for this purchase can be found here. Insiders purchased 519,100 shares of company stock valued at $17,970,882 over the last 90 days. 15.00% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. raised its holdings in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 180 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares in the last quarter. Sei Investments Co. raised its holdings in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in Radius Health by 4.1% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 690 shares in the last quarter. Finally, California Public Employees Retirement System raised its holdings in Radius Health by 2.3% in the second quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock worth $3,238,000 after purchasing an additional 1,600 shares in the last quarter.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.